Jazz Pharmaceuticals has agreed to acquire Actio Biosciences, the San Diego, California-based clinical-stage biotech, for $820 million upfront plus up to $500 million in additional contingent payments, a deal worth as much as $1.32 billion depending on the drug candidate’s progress. The acquisition centers on ABS-1230, a first-in-class KCNT1 ion channel inhibitor being developed for KCNT1-related epilepsy, an ultra-rare genetic condition that affects an estimated 2,500 patients in the U.S. The deal is expected to close in the fourth quarter of 2026, funded through Jazz’s cash on hand and existing financing facilities, and has been unanimously approved by both companies’ boards.
What Jazz Is Actually Buying
ABS-1230 has already picked up FDA Fast Track, Rare Pediatric Disease, and Orphan Drug designations, and is currently in the Phase 1b/2a KYRON trial, which Jazz says is designed to serve as the registrational study supporting an eventual FDA submission. The program was also accepted into the FDA’s newer Rare Disease Evidence Principles process, aimed at streamlining development pathways for ultra-rare conditions with small patient populations. Jazz CEO Renee Gala framed the deal as building directly on the company’s existing epilepsy business: “The acquisition of ABS-1230 represents a highly strategic expansion of our rare epilepsy portfolio, building upon the global success of Epidiolex and deepening our leadership in rare and severe epilepsies. The emerging clinical profile of ABS-1230 is highly encouraging, and we look forward to closing the proposed transaction and collaborating with our new Actio Biosciences colleagues to address an urgent patient need.” Actio Biosciences CEO David Goldstein described the choice of partner as a matter of scale: “We chose to partner with Jazz because they combine a purpose-led culture with a world-class development engine and the commercial scale to ensure ABS-1230 is brought to patients as quickly and efficiently as possible.”
What Happens to the Rest of Actio
The deal isn’t a full corporate acquisition. Alongside the ABS-1230 sale, Actio Biosciences will spin out its remaining pipeline into an independent, privately held company focused on genetic rare neurological diseases, including ABS-0871, a TRPV4 inhibitor being developed for Charcot-Marie-Tooth disease. That structure lets Jazz acquire the single asset it wants most while Actio’s other rare-disease science continues under separate ownership rather than being absorbed or shelved.
A Global Biopharma in Philadelphia
Jazz Pharmaceuticals is headquartered in Dublin, Ireland, and its reach extends far past that home base, the company’s medicines now reach patients in nearly 100 countries, backed by a commercial and operational footprint built to move quickly from approval to patient access Among its North American locations, Jazz maintains an office in Philadelphia, PA , giving the company an active presence in the Greater Philadelphia region. For a company managing a global rare disease portfolio spanning epilepsy, cancer, and sleep disorders, that Philadelphia office is one more sign of how spread out the modern biopharma map has become, with deal-making, R&D, and commercial operations rarely concentrated in a single city anymore
